PTC Therapeutics Inc (NAS:PTCT)
$ 36.53 3.23 (9.7%) Market Cap: 2.80 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

PTC Therapeutics Inc at Evercore HealthCONx Conference Transcript

Dec 03, 2019 / 07:45PM GMT
Release Date Price: $49.96 (+4.94%)
Unidentified Analyst

Okay. We're going to get started with our next panel, which I'm so excited about because it bridges some of the exciting news I've been seeing in gene therapy into some companies that are kind of hybrid, traditional biotech companies as we know them, with small molecules and biologics, but also their foray into the world of gene therapy.

Could have also [called] the panel, are you kidding me? After the Audentes acquisition for like $3 billion last night. And looking at the companies here and they're like, wait a minute, are you kidding me? Like help me understand the math here as we think about valuation.

So we have Stuart Peltz, Chief Executive Officer of PTC Therapeutics; Bradley Campbell, President and Chief Operating Officer from Amicus; and Shalini Sharp, Chief Financial Officer of Ultragenyx. And as we think about the portfolios represented here, we've actually got some exciting gene therapy efforts, some exciting traditional efforts.

So Shalini, let's start with you first. Just set the stage for us, give us a quick snapshot of Ultragenyx traditional orphan

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot